These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 22895833)

  • 1. Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice.
    Kaneko A; Hirano Y; Fujibayashi T; Hattori Y; Terabe K; Kojima T; Ishiguro N
    Mod Rheumatol; 2013 May; 23(3):466-77. PubMed ID: 22895833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients.
    Koike T; Harigai M; Ishiguro N; Inokuma S; Takei S; Takeuchi T; Yamanaka H; Tanaka Y
    Mod Rheumatol; 2012 Aug; 22(4):498-508. PubMed ID: 21993918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: Results from registered data analyses.
    Nakashima Y; Miyahara H; Kondo M; Fukuda T; Harada H; Haraguchi A; Inoue Y; Ishinishi T; Maekawa M; Maeyama A; Nakashima M; Shono E; Suematsu E; Shimauchi T; Tsuru T; Tsukamoto H; Yoshizawa S; Yoshizawa S; Iwamoto Y
    Mod Rheumatol; 2017 Jan; 27(1):15-21. PubMed ID: 27142240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis.
    Keystone EC; van der Heijde D; Kavanaugh A; Kupper H; Liu S; Guérette B; Mozaffarian N
    J Rheumatol; 2013 Sep; 40(9):1487-97. PubMed ID: 23818718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
    Detert J; Bastian H; Listing J; Weiß A; Wassenberg S; Liebhaber A; Rockwitz K; Alten R; Krüger K; Rau R; Simon C; Gremmelsbacher E; Braun T; Marsmann B; Höhne-Zimmer V; Egerer K; Buttgereit F; Burmester GR
    Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.
    Takeuchi T; Yamanaka H; Ishiguro N; Miyasaka N; Mukai M; Matsubara T; Uchida S; Akama H; Kupper H; Arora V; Tanaka Y
    Ann Rheum Dis; 2014 Mar; 73(3):536-43. PubMed ID: 23316080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.
    Soubrier M; Puéchal X; Sibilia J; Mariette X; Meyer O; Combe B; Flipo RM; Mulleman D; Berenbaum F; Zarnitsky C; Schaeverbeke T; Fardellone P; Dougados M
    Rheumatology (Oxford); 2009 Nov; 48(11):1429-34. PubMed ID: 19741011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
    Keystone EC; Haraoui B; Guérette B; Mozaffarian N; Liu S; Kavanaugh A
    J Rheumatol; 2014 Feb; 41(2):235-43. PubMed ID: 24293583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.
    Yamanaka H; Ishiguro N; Takeuchi T; Miyasaka N; Mukai M; Matsubara T; Uchida S; Akama H; Kupper H; Arora V; Tanaka Y
    Rheumatology (Oxford); 2014 May; 53(5):904-13. PubMed ID: 24441150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients.
    Kimura N; Suzuki K; Takeuchi T
    Mod Rheumatol; 2016 Sep; 26(5):676-80. PubMed ID: 26708943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study.
    Kavanaugh A; Fleischmann RM; Emery P; Kupper H; Redden L; Guerette B; Santra S; Smolen JS
    Ann Rheum Dis; 2013 Jan; 72(1):64-71. PubMed ID: 22562973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study.
    Heiberg MS; Rødevand E; Mikkelsen K; Kaufmann C; Didriksen A; Mowinckel P; Kvien TK
    Ann Rheum Dis; 2006 Oct; 65(10):1379-83. PubMed ID: 16679432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients.
    Katayama K; Matsuno T
    Mod Rheumatol; 2009; 19(5):513-21. PubMed ID: 19603251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients.
    Ito S; Kobayashi D; Hasegawa E; Takai C; Nemoto T; Lee H; Abe A; Otani H; Ishikawa H; Murasawa A; Narita I; Nakazono K
    Intern Med; 2019 Feb; 58(4):511-519. PubMed ID: 30210123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis.
    Finzel S; Kraus S; Figueiredo CP; Regensburger A; Kocijan R; Rech J; Schett G
    Ann Rheum Dis; 2019 Sep; 78(9):1186-1191. PubMed ID: 31142474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.
    Smolen JS; Emery P; Fleischmann R; van Vollenhoven RF; Pavelka K; Durez P; Guérette B; Kupper H; Redden L; Arora V; Kavanaugh A
    Lancet; 2014 Jan; 383(9914):321-32. PubMed ID: 24168956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study.
    Hirata S; Saito K; Kubo S; Fukuyo S; Mizuno Y; Iwata S; Nawata M; Sawamukai N; Nakano K; Yamaoka K; Tanaka Y
    Arthritis Res Ther; 2013 Sep; 15(5):R135. PubMed ID: 24286472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.